Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.63 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.63 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.63 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.63 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8249950 | 0.87 | PRKD3 (0.50) | TGFBR1PRKD3PRKD1PRKD2GRM4 | |
| SCHEMBL2125422 | 0.87 | TGFBR1 (0.50) | TGFBR1PRKD3PRKD1PRKD2GRM4 | |
| SCHEMBL27712137 | 0.82 | TGFBR1 (0.57) | TGFBR1PRKD3PRKD1PRKD2GRM4 | |
| SCHEMBL5551427 | 0.79 | PRKD3 (0.48) | TGFBR1PRKD3PRKD1PRKD2SLC40A1 | |
| SCHEMBL5555284 | 0.79 | PRKD3 (0.45) | TGFBR1PRKD3PRKD1PRKD2GRM4 | |
| SCHEMBL29361383 | 0.78 | TGFBR1 (1.00) | TGFBR1PRKD3PRKD1PRKD2GRM4 | |
| SCHEMBL411646 | 0.78 | TGFBR1 (1.00) | TGFBR1PRKD3PRKD1PRKD2GRM4 | |
| SCHEMBL29381400 | 0.78 | TGFBR1 (1.00) | TGFBR1PRKD3PRKD1PRKD2GRM4 | |
| SCHEMBL30901626 | 0.77 | TGFBR1 (0.55) | TGFBR1PRKD3PRKD1PRKD2GRM4 | |
| SCHEMBL14778537 | 0.77 | TGFBR1 (0.55) | TGFBR1PRKD3PRKD1PRKD2GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293500-A1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293500-A1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293500-A1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7232824-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232824-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232824-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-20050096333-A1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2005-05-05 | — | — | US | disclosed |
| WO-2005032481-A2 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC. (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096333-A1 | Quinazoline derivatives as medicaments | HRH4, HRH2, HRH3 | TGFBR1 70/4885PRKD3 3011/4885PRKD1 3332/4885 |
| US-20070293500-A1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SMAD3, SMAD2, TGFB2 | TGFBR1 8/4885PRKD3 1661/4885PRKD1 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.